Use of an adjuvanted allergy vaccine formulation for parenteral administration

A parenteral, multipurpose technology applied in the field of seasonal allergen compositions, which can solve problems such as inability to vaccinate against allergies

Inactive Publication Date: 2010-03-17
ALK ABELLO SA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this measure cannot be used for allergy vaccination due to the pathological immune response already carried out

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Example 1: The dose is increased during the season, with subcutaneous allergy vaccine

[0100] introduction

[0101] Generally, in terms of seasonal allergens, such as pollen, immunotherapy before the coming of the season is recommended, which means that the immunotherapy has to be started before the coming of the allergen season, for example, 11-16 weeks. This leads to the fact that the patient has to start treatment when he or she is completely asymptomatic and does not feel the need for treatment. Therefore, many patients do not initiate immunotherapy because they usually do not see a doctor unless they already have symptoms. Compared with the use of symptom-relieving drugs to treat allergies, the initiation of treatment during the season will allow more patients to enter the cause of allergic diseases, that is, immunotherapy.

[0102] In this example, the safety of initiating immunotherapy for subcutaneous allergy vaccines during the season was studied.

[0103] Resear...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of a seasonal allergen composition for the manufacture of a vaccine formulation for preventing or treating allergy to the allergen composition in a subject byparenteral administration, wherein the vaccine formulation is administered in a dosage regimen comprising an up-dosing phase, wherein the up-dosing phase partly or wholly overlaps with the allergen season of the allergen composition.

Description

Technical field [0001] The present invention relates to a seasonal allergen composition for preparing a vaccine formulation for the prevention or treatment of allergies in a subject by parenteral administration, wherein the vaccine formulation includes a dose escalation phase and a maintenance dose phase. Dosing schedule administration. Background technique [0002] Allergy is a major health problem in countries that adopt Western lifestyles. In addition, the prevalence of allergic diseases is gradually increasing in these countries. Although allergic diseases are not generally regarded as life-threatening diseases, they can develop into asthma that causes a large number of deaths every year. In Western countries, the special epidemic, which accounts for about 30% of young people, causes significant loss of quality of life, working days and income, and is one of the major health problems. [0003] Allergy is a complex disease. Many factors contribute to sensitization events. O...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/36
CPCA61K39/001
Inventor E·G·维斯滕贝格
Owner ALK ABELLO SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap